D005169Chemicals & DrugsD12.776.124.125.350D23.119.3506260.970748Factor VIIIFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson29399993Spena S, Garagiola I, Cannav? A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi FJournal of thrombosis and haemostasis : JTHPrediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 04; 16(4):778-790.J Thromb Haemost2018-03-23T00:00:002018Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.4.768090.01424186research area of0.7955860.014670926subject area forPediatricsNarineHakobyanNarine Hakobyan349102Hakobyan, NarineAssistant ProfessorMindySimpsonMindy Simpson349108Simpson, MindyAssistant ProfessorLisaBoggioLisa Boggio349587Boggio, LisaAssistant ProfessorDusanStefoskiDusan Stefoski349679Stefoski, DusanAssociate Professor6Assistant Professor5Associate Professor4Professor32020842Simpson ML, Desai V, Maro GS, Yan SJournal of managed care & specialty pharmacyComparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.J Manag Care Spec Pharm2020-02-05T00:00:002020Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.32410165Lalezari S, Acquadro M, de Bock E, Lambert J, Simpson MLAdvances in therapyComparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.Adv Ther2020-05-14T00:00:002020Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis.32820685Yan S, Maro GS, Desai V, Simpson MLJournal of managed care & specialty pharmacyA Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.J Manag Care Spec Pharm2020-08-21T00:00:002020A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.33296943Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson MLThrombosis and haemostasisDecreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.Thromb Haemost2020-12-09T00:00:002020Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.Neurological SciencesAnatomy and Cell BiologyRush University, Rush Medical CollegeDale (Rick)SumnerDale (Rick) Sumner41.87328300000000-87.66936330000000349028Sumner, Dale (Rick)0000-0001-9575-3862Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professor